| General Information of Drug Metabolite (DM) (ID: DM000457) |
| DM Name |
AGN 190844
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 2C8 (CYP2C8)
|
DME0018
|
| Oxidation - Oxidation |
Tazarotene
|
[1] , [2] , [3] |
|
Flavin-containing monooxygenase (FMO)
|
DMEN075
|
| Oxidation - Oxidation |
Tazarotene
|
[1] , [2] , [3] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| Tazarotene |
DR1536
|
Approved |
Psoriasis vulgaris |
|
|
| References |
| 1 |
Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis Clin Pharmacokinet. 1999 Oct;37(4):273-87. doi: 10.2165/00003088-199937040-00001.
|
| 2 |
Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans. Drug Metab Dispos. 2003 Apr;31(4):476-81.
|
| 3 |
LABEL:AZAROTENE aerosol, foam
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
